LabCorp

Patient Report

Rte: 00

Phone: (800) 539-6119

Specimen ID: Control ID:

Acct #: 17452095 Walk-In Lab. LLC

1645 Tiffany Lane

Mandeville L-A 7044&--- -----

**Patient Details** Specimen Details Physician Details Date collected: Ordering: S HARDIN DOB: Date received: Referring: Age(y/m/d): Gender: SSN: Date entered: ID: 1881658094 Patient ID: Date reported: NPI: 1881658094

## **General Comments & Additional Information**

Alternate Control Number:
Total Volume: Not Provided

Alternate Patient ID: Not Provided Fasting: U

## **Ordered Items**

N-Telopeptide, Urine; Drawing Fee

TESTS	RESULT	FLAG	UNITS REF	FERENCE INTERVAL	LAB
N-Telopeptide, Urine					
N-telopeptide	77		nmol BCE	Not Estab.	01
Creatinine, Urine	25.5		mg/dL	Not Estab.	02
N-telo/Creat. Ratio	34	1	nM BCE/mM Cr	0 - 89	
Interpretive Guide:					01

The N-telopeptide and Creatinine are used to calculate the N-telo/Creat. Ratio which is referred to as "NTx". Suggested guidelines for the clinical use of NTx are as follows:

1. Menopausal Women not on Hormone Replacement Therapy (HRT): Women with a baseline NTx value >38 are at significant risk for a decrease in bone mineral density (BMD) after 1 year compared to women on HRT. The probability of a decline in BMD increases with NTx value as follows: (1):

Baseline NTx Probability of Decrease in BMD 18-38 1.4 p=0.28 38-51 2.5 p=0.03 51-67 3.8 p=0.0006 67-188 17.3 p=0.0001

- 2. Menopausal Women Receiving Antiresorptive Therapy: The probability that treatment is effective after three months is increased when the measured NTx value is <or=38 nM BCE/mM CRT, or NTx has decreased >or=30% from baseline.[1]
- 3. Patients with Paget's Disease of Bone:
  The probability that treatment is effective after one
  month is increased when the measured NTx value is within
  the reference range, or NTx has decreased >or=30%
  from baseline.[2]
  - 1. Chesnut CH, Bell NH, Clark GS, et al. Am J Med, 102:29-37,1997. (1):M757, 1996.
  - 2. Bone H, Tucci J, et al. J Bone Min Res.11(1):M757,1996

LabCorp Patient Report

Patient:
DOB: Patient ID: Specimen ID:
Dots Control ID: Date collected:

01 BN LabCorp Burlington Dir: William F Hancock, MD

1447 York Court, Burlington, NC 27215-3361

02 DA LabCorp Dallas Dir: CN Etufugh, MD 7777 Forest Lane Suite C350, Dallas, TX 75230-2544

For inquiries, the physician may contact Branch: 504-828-2666 Lab: 800-762-4344

